Compositions, Methods and/or Devices For Prevention and/or Treatment Of Dry Eye Disorders
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to compositions, methods and devices for treating, reducing or preventing one or more eye disorders, particularly dry eye disorders, in a subject by administering an amount of one or more fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity while permitting bacterial growth or without substantially altering the dynamic microbial community of the eye. Typically, the fatty acids and/or fatty acid esters are C8 to C16 fatty acids and/or fatty acid esters.
-
Citations
46 Claims
-
1-23. -23. (canceled)
-
24. A method for treating or preventing a dry eye disorder in a subject by administering to the subject'"'"'s eye a composition with an amount of one or more C8 to C16 fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity without substantially altering the dynamic microbial community of the subject'"'"'s eye to which the composition has been administered;
wherein the amount of one or more C6 to C16 fatty acids and/or fatty acid esters is in a concentration of between 2.5 μ
g/ml to 15 μ
g/ml in the composition.- View Dependent Claims (25, 28, 29, 30, 31, 32)
-
26-27. -27. (canceled)
-
33-34. -34. (canceled)
-
39. (canceled)
-
41. The method of claim 35, wherein the amount of lauric acid included in the eye drops or associated with the contact lenses is in a concentration of about 2.5 μ
- g/ml to 15 μ
g/ml.
- g/ml to 15 μ
-
41-45. -45. (canceled)
-
46. The method according to one or more of the above method claims, wherein the amount of one or more C8 to C16 fatty acids and/or fatty acid esters therapeutically effective to inhibit lipase activity in the subject'"'"'s eye while permitting bacterial growth in the subject'"'"'s eye.
Specification